Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News Notable Notes: Kotak Initiates Coverage Of Five Indian CMO, CRO Firms

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country

You may also be interested in...



PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India

NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales

PharmAsia News Notable Notes: CRO/CMO Divis Labs Has “Maximum Upside Potential” In India

NEW DELHI - Kotak Institutional Equities has raised its price target for Hyderabad, India-based Divis Laboratories citing growing contract research and manufacturing as well as generic sales

PharmAsia News Notable Notes: India’s Sun, Dishman Price Targets Raised By Citigroup, Dr Reddy’s Maintained As Hold

NEW DELHI - Following fourth quarter earnings, Citigroup Global Markets hiked the price target for India's Sun and Dishman pharmaceutical companies citing strong and robust guidance and maintained a hold rating on Dr Reddy's saying management needed to present more clarity

Related Content

UsernamePublicRestriction

Register

SC068635

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel